文献速递腹部心血管CT

双层光谱CT碘与细胞外容积生物标志物无创评估Fontan相关肝病肝纤维化

Dual-layer spectral CT-derived iodine and extracellular volume biomarkers for noninvasive assessment of hepatic fibrosis in Fontan-associated liver disease.
PubMed 文献 · Abdom Radiol (NY) · 2026-10-22

本研究为单中心探索性回顾性研究,纳入23例Fontan相关肝病患者,评估延迟期双层光谱CT衍生的标准化碘浓度和细胞外容积分数对肝纤维化的诊断效能,以METAVIR分期为参考标准。结果显示ECV与纤维化分期显著相关,对进展期纤维化(≥F3)AUC为0.902,对肝硬化(F4)AUC为0.833。

要点

  • 延迟期双层光谱CT衍生的ECV与Fontan相关肝病肝纤维化分期显著正相关。
  • ECV对进展期纤维化(≥F3)AUC为0.902,对肝硬化(F4)AUC为0.833。
  • 肝硬化诊断切点43.45%时敏感度87.5%、特异度80.0%、阴性预测值92.3%。

核心结论

  • 延迟期双层光谱CT衍生的ECV与组织学纤维化严重程度显著相关,对进展期纤维化和肝硬化显示初步鉴别能力。
  • 标准化碘浓度与纤维化分期仅呈弱正相关,有序趋势未达统计学显著性。
  • 临床推广应用前需在更大规模独立Fontan队列中进行外部验证。

研究设计与样本

  • 标准化碘浓度计算为肝脏碘浓度除以主动脉碘浓度;ECV通过延迟期碘密度图经血细胞比容校正计算。
  • 以基于METAVIR系统的组织学纤维化分期为参考标准。

关键影像表现/征象

  • ECV在进展期纤维化分期中更高,F1中位数39.21%、F2为37.15%、F3为42.72%、F4为46.78%。
  • ECV在不同纤维化分期之间差异显著(p=0.014),呈显著有序趋势(p<0.001),与组织学分期正相关(ρ=0.666,p<0.001)。
  • 标准化碘浓度与纤维化分期呈弱正相关,但有序趋势未达统计学显著性。

诊断标准与关键数值

  • ECV对进展期纤维化(≥F3)的AUC为0.902(95% CI,0.766-1.000)。
  • ECV对肝硬化(F4)的AUC为0.833(95% CI,0.655-1.000),切点43.45%时敏感度87.5%、特异度80.0%、阴性预测值92.3%。

临床应用与阅片要点

  • 延迟期双层光谱CT衍生的ECV可作为Fontan相关肝病肝纤维化无创评估的潜在影像生物标志物。
  • ECV对肝硬化阴性预测值较高(92.3%),有助于排除肝硬化,但阳性预测需结合其他临床信息。
  • 标准化碘浓度对纤维化分期的鉴别价值有限,不宜单独用于分期。

局限性

  • 单中心探索性回顾性研究,样本量仅23例,可能存在选择偏倚。
  • 需在更大规模独立Fontan队列中进行外部验证后方可临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To evaluate the diagnostic performance of delayed-phase dual-layer spectral CT-derived normalized iodine concentration and extracellular volume fraction for noninvasive assessment of hepatic fibrosis in patients with Fontan-associated liver disease.

METHODS: This single-center exploratory retrospective study included 23 patients with Fontan-associated liver disease who underwent both liver biopsy and delayed-phase dual-layer spectral CT between January 2021 and December 2023. Normalized iodine concentration was calculated as hepatic iodine concentration divided by aortic iodine concentration. Hematocrit-adjusted extracellular volume fraction (ECV) was calculated from delayed-phase iodine-density maps. Histologic fibrosis stage based on the METAVIR system was used as the reference standard. Associations between CT biomarkers and fibrosis stage were assessed using the Kruskal-Wallis test, Jonckheere-Terpstra trend test, and Spearman correlation. Diagnostic performance for advanced fibrosis (≥ F3) and cirrhosis (F4) was evaluated using receiver operating characteristic analysis.

RESULTS: Histologic fibrosis stages were F1 in 4 patients, F2 in 2, F3 in 9, and F4 in 8. ECV was higher in advanced fibrosis stages, with median values of 39.21% in F1, 37.15% in F2, 42.72% in F3, and 46.78% in F4. ECV differed significantly among fibrosis stages (p = 0.014), showed a significant ordered trend (p < 0.001), and correlated positively with histologic stage (ρ = 0.666, p < 0.001). IC-normalized showed a weak positive correlation with fibrosis stage, but the ordered trend did not reach statistical significance. For advanced fibrosis, ECV showed promising preliminary discrimination, with an AUC of 0.902 (95% CI, 0.766-1.000). For cirrhosis, ECV showed an AUC of 0.833 (95% CI, 0.655-1.000), with sensitivity of 87.5%, specificity of 80.0%, and negative predictive value of 92.3% at a cutoff of 43.45%.

CONCLUSION: In this single-center exploratory study, delayed-phase dual-layer spectral CT-derived ECV showed a significant association with histologic fibrosis severity and promising preliminary discrimination for advanced fibrosis and cirrhosis in Fontan-associated liver disease. External validation in larger, independent Fontan cohorts is required before clinical application.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Inmutto N, Srisuwan T, Nimitrungtawee N, et al. Dual-layer spectral CT-derived iodine and extracellular volume biomarkers for noninvasive assessment of hepatic fibrosis in Fontan-associated liver disease. Abdom Radiol (NY). 2026. PMID: 42911394. doi:10.1007/s00261-026-05835-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。